Drug Sensitivity Profiling of Multiple Myeloma Cell Lines

HMCLs were cultured in RPMI-1640 medium (Gibco, Thermo Fisher Scientific, Waltham, Massachusetts, USA) supplemented with fetal bovine serum (FBS, Eurobio, Les Ulis, France) (10%) and Interleukin 6 (IL6, Peprotech, Rocky Hill, New Jersey, USA) for XG cell lines. We evaluated the sensitivity of the cell lines to ten drugs, including Bortezomib (Euromedex), Melphalan (HAC Pharma), Lenalidomide (Selleckchem), Pomalidomide (Selleckchem), IKK2 inhibitor (AS602868), CDK inhibitor (AT7519 CDK1/2/4/5/6/9i, Selleckchem), TSA (Trichostatin A, HDACi, Sigma), SAHA (Suberanilohydroxamic acid, HDACi, Selleckchem), Panabinostat (HDACi, Selleckchem) and Dexamethasone. For a given drug, HMCLs were treated with different concentrations. The IC₅₀was determined at day 4 using the CellTiter-Glo assay (Promega, Madison, Wisconsin, USA), as previously described 28 (link),29 (link). The data represent the mean ± standard deviation of three independent experiments that were carried out on sextuplet culture wells (Table S3). The subset of HMCLs used for analyses were characterized, for drug response, in previous studies 28 (link),30 (link)-34 (link) and selected according to the different molecular subgroups previously described by transcriptomic analyzes 8 (link).